JP2020511506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511506A5 JP2020511506A5 JP2019551998A JP2019551998A JP2020511506A5 JP 2020511506 A5 JP2020511506 A5 JP 2020511506A5 JP 2019551998 A JP2019551998 A JP 2019551998A JP 2019551998 A JP2019551998 A JP 2019551998A JP 2020511506 A5 JP2020511506 A5 JP 2020511506A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- pyrrole
- hexahydropyrrolo
- diethyl
- dihydrofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 158
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 108
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 78
- 150000001875 compounds Chemical class 0.000 claims description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 48
- -1 heptane-2-yl Chemical group 0.000 claims description 48
- 239000001257 hydrogen Substances 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 125000001188 haloalkyl group Chemical group 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000012453 solvate Substances 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 16
- 150000004677 hydrates Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 12
- NAGYJALPUMNLDF-IBGZPJMESA-N (3R)-3-[2-(2-phenyl-2,6-diazaspiro[3.3]heptan-6-yl)ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound C1(=CC=CC=C1)N1CC2(CN(C2)CC[C@@H]2OC(C3(C2)CCCCC3)=O)C1 NAGYJALPUMNLDF-IBGZPJMESA-N 0.000 claims description 6
- GPEBSCOTYHNLQY-FQEVSTJZSA-N (3R)-3-[2-[2-(2,6-dimethylpyridin-4-yl)-2,6-diazaspiro[3.3]heptan-6-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC(=CC(=C1)N1CC2(CN(C2)CC[C@@H]2OC(C3(C2)CCCCC3)=O)C1)C GPEBSCOTYHNLQY-FQEVSTJZSA-N 0.000 claims description 6
- UMHAYUZBFPAKJI-IBGZPJMESA-N (3R)-3-[2-[2-(2-methylpyridin-4-yl)-2,6-diazaspiro[3.3]heptan-6-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC=CC(=C1)N1CC2(CN(C2)CC[C@@H]2OC(C3(C2)CCCCC3)=O)C1 UMHAYUZBFPAKJI-IBGZPJMESA-N 0.000 claims description 6
- UOVKZNUMVOSVCG-SFHVURJKSA-N (3R)-3-[2-[2-(3-methylpyridin-4-yl)-2,6-diazaspiro[3.3]heptan-6-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC=1C=NC=CC=1N1CC2(CN(C2)CC[C@@H]2OC(C3(C2)CCCCC3)=O)C1 UOVKZNUMVOSVCG-SFHVURJKSA-N 0.000 claims description 6
- KEZUVWCNQURYDI-AOMIVXANSA-N (3R)-3-[2-[5-(2,6-dimethylpyridin-4-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC(=CC(=C1)N1CC2C(C1)CN(C2)CC[C@@H]1OC(C2(C1)CCCCC2)=O)C KEZUVWCNQURYDI-AOMIVXANSA-N 0.000 claims description 6
- OSLDCYYEHVTPFN-GRERDSQWSA-N (3R)-3-[2-[5-(2-methylpyridin-4-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC=CC(=C1)N1CC2C(C1)CN(C2)CC[C@@H]1OC(C2(C1)CCCCC2)=O OSLDCYYEHVTPFN-GRERDSQWSA-N 0.000 claims description 6
- HVGOSLKNDABISN-MHJFOBGBSA-N (3R)-3-[2-[5-(3-methylpyridin-4-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC=1C=NC=CC=1N1CC2C(C1)CN(C2)CC[C@@H]1OC(C2(C1)CCCCC2)=O HVGOSLKNDABISN-MHJFOBGBSA-N 0.000 claims description 6
- NAGYJALPUMNLDF-LJQANCHMSA-N (3S)-3-[2-(2-phenyl-2,6-diazaspiro[3.3]heptan-6-yl)ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound C1(=CC=CC=C1)N1CC2(CN(C2)CC[C@H]2OC(C3(C2)CCCCC3)=O)C1 NAGYJALPUMNLDF-LJQANCHMSA-N 0.000 claims description 6
- GPEBSCOTYHNLQY-HXUWFJFHSA-N (3S)-3-[2-[2-(2,6-dimethylpyridin-4-yl)-2,6-diazaspiro[3.3]heptan-6-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC(=CC(=C1)N1CC2(CN(C2)CC[C@H]2OC(C3(C2)CCCCC3)=O)C1)C GPEBSCOTYHNLQY-HXUWFJFHSA-N 0.000 claims description 6
- UMHAYUZBFPAKJI-LJQANCHMSA-N (3S)-3-[2-[2-(2-methylpyridin-4-yl)-2,6-diazaspiro[3.3]heptan-6-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC=CC(=C1)N1CC2(CN(C2)CC[C@H]2OC(C3(C2)CCCCC3)=O)C1 UMHAYUZBFPAKJI-LJQANCHMSA-N 0.000 claims description 6
- UOVKZNUMVOSVCG-GOSISDBHSA-N (3S)-3-[2-[2-(3-methylpyridin-4-yl)-2,6-diazaspiro[3.3]heptan-6-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC=1C=NC=CC=1N1CC2(CN(C2)CC[C@H]2OC(C3(C2)CCCCC3)=O)C1 UOVKZNUMVOSVCG-GOSISDBHSA-N 0.000 claims description 6
- KEZUVWCNQURYDI-QETWGEEDSA-N (3S)-3-[2-[5-(2,6-dimethylpyridin-4-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC(=CC(=C1)N1CC2C(C1)CN(C2)CC[C@H]1OC(C2(C1)CCCCC2)=O)C KEZUVWCNQURYDI-QETWGEEDSA-N 0.000 claims description 6
- OSLDCYYEHVTPFN-GZNCHQMQSA-N (3S)-3-[2-[5-(2-methylpyridin-4-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC1=NC=CC(=C1)N1CC2C(C1)CN(C2)CC[C@H]1OC(C2(C1)CCCCC2)=O OSLDCYYEHVTPFN-GZNCHQMQSA-N 0.000 claims description 6
- HVGOSLKNDABISN-SOAGJPPSSA-N (3S)-3-[2-[5-(3-methylpyridin-4-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]ethyl]-2-oxaspiro[4.5]decan-1-one Chemical compound CC=1C=NC=CC=1N1CC2C(C1)CN(C2)CC[C@H]1OC(C2(C1)CCCCC2)=O HVGOSLKNDABISN-SOAGJPPSSA-N 0.000 claims description 6
- LJLCWZRSQCEMOL-SFHVURJKSA-N (5R)-3,3-diethyl-5-[2-(2-phenyl-2,6-diazaspiro[3.3]heptan-6-yl)ethyl]oxolan-2-one Chemical compound C(C)C1(C(O[C@H](C1)CCN1CC2(C1)CN(C2)C1=CC=CC=C1)=O)CC LJLCWZRSQCEMOL-SFHVURJKSA-N 0.000 claims description 6
- RBXFBWXIVPJFAU-QLOJAFMTSA-N (5R)-3,3-diethyl-5-[2-(5-phenyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl)ethyl]oxolan-2-one Chemical compound C(C)C1(C(O[C@H](C1)CCN1CC2CN(CC2C1)C1=CC=CC=C1)=O)CC RBXFBWXIVPJFAU-QLOJAFMTSA-N 0.000 claims description 6
- LJLCWZRSQCEMOL-GOSISDBHSA-N (5S)-3,3-diethyl-5-[2-(2-phenyl-2,6-diazaspiro[3.3]heptan-6-yl)ethyl]oxolan-2-one Chemical compound C(C)C1(C(O[C@@H](C1)CCN1CC2(C1)CN(C2)C1=CC=CC=C1)=O)CC LJLCWZRSQCEMOL-GOSISDBHSA-N 0.000 claims description 6
- RBXFBWXIVPJFAU-AFMYVXGZSA-N (5S)-3,3-diethyl-5-[2-(5-phenyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl)ethyl]oxolan-2-one Chemical compound C(C)C1(C(O[C@@H](C1)CCN1CC2CN(CC2C1)C1=CC=CC=C1)=O)CC RBXFBWXIVPJFAU-AFMYVXGZSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102100028662 Sigma intracellular receptor 2 Human genes 0.000 claims description 4
- 101710109012 Sigma intracellular receptor 2 Proteins 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000008482 dysregulation Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims 1
- 0 C*1(C)CCN(*)CC1 Chemical compound C*1(C)CCN(*)CC1 0.000 description 6
- 206010027175 memory impairment Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023174368A JP7781122B2 (ja) | 2017-03-21 | 2023-10-06 | シグマ－２受容体の新規調節物質およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762474277P | 2017-03-21 | 2017-03-21 | |
| US62/474,277 | 2017-03-21 | ||
| PCT/US2018/022574 WO2018175188A1 (en) | 2017-03-21 | 2018-03-15 | Novel modulators of the sigma-2 receptor and their method of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174368A Division JP7781122B2 (ja) | 2017-03-21 | 2023-10-06 | シグマ－２受容体の新規調節物質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511506A JP2020511506A (ja) | 2020-04-16 |
| JP2020511506A5 true JP2020511506A5 (enExample) | 2021-04-22 |
| JP7365237B2 JP7365237B2 (ja) | 2023-10-19 |
Family
ID=63585700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551998A Active JP7365237B2 (ja) | 2017-03-21 | 2018-03-15 | シグマ－２受容体の新規調節物質およびその使用方法 |
| JP2023174368A Active JP7781122B2 (ja) | 2017-03-21 | 2023-10-06 | シグマ－２受容体の新規調節物質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174368A Active JP7781122B2 (ja) | 2017-03-21 | 2023-10-06 | シグマ－２受容体の新規調節物質およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10961249B2 (enExample) |
| EP (1) | EP3600290B1 (enExample) |
| JP (2) | JP7365237B2 (enExample) |
| MA (1) | MA49019A (enExample) |
| WO (1) | WO2018175188A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014164756A1 (en) | 2013-03-11 | 2014-10-09 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| EP3200589A4 (en) | 2014-09-10 | 2018-07-25 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| EP3541790B1 (en) | 2016-11-15 | 2025-09-03 | Temple University - Of The Commonwealth System of Higher Education | 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression |
| WO2018175188A1 (en) * | 2017-03-21 | 2018-09-27 | Temple University-Of The Commonwealth System Of Higher Education | Novel modulators of the sigma-2 receptor and their method of use |
| JP7365238B2 (ja) * | 2017-03-21 | 2023-10-19 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | ５－ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用 |
| TW202523659A (zh) * | 2018-05-11 | 2025-06-16 | 美國坦普大學 高等教育聯邦系統 | 作為5-羥基色胺受體7之調節劑之新穎官能化內醯胺及其使用方法 |
| GB201809295D0 (en) * | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| EP3978497A4 (en) * | 2019-05-30 | 2022-07-13 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | FUSED CYCLIC COMPOUND, METHOD FOR PREPARING IT AND ITS USE |
| EP4568968A1 (en) * | 2022-08-11 | 2025-06-18 | Remynd N.V. | (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435830B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| EP2081575A4 (en) | 2006-11-13 | 2010-01-06 | King Pharmaceuticals Res & Dev | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR |
| US8148408B2 (en) | 2008-05-09 | 2012-04-03 | Abbott Laboratories | Selective substituted pyridine ligands for neuronal nicotinic receptors |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| WO2014085413A1 (en) | 2012-11-28 | 2014-06-05 | Temple University - Of The Commonwealth System Of Higher Education | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators |
| SG11201504410PA (en) * | 2012-12-07 | 2015-07-30 | Chemocentryx Inc | Diazole lactams |
| WO2014164756A1 (en) | 2013-03-11 | 2014-10-09 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| KR20160098506A (ko) | 2013-12-20 | 2016-08-18 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 통증에 대한 다양한 활성을 갖는 피페라진 유도체 |
| EP3200589A4 (en) | 2014-09-10 | 2018-07-25 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| EP3204383B1 (en) | 2014-10-08 | 2020-11-18 | F.Hoffmann-La Roche Ag | Spirodiamine derivatives as aldosterone synthase inhibitors |
| TWI770525B (zh) | 2014-12-30 | 2022-07-11 | 美商瓦洛健康公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| WO2016183150A1 (en) | 2015-05-12 | 2016-11-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
| EP3541790B1 (en) | 2016-11-15 | 2025-09-03 | Temple University - Of The Commonwealth System of Higher Education | 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression |
| JP7365238B2 (ja) | 2017-03-21 | 2023-10-19 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | ５－ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用 |
| WO2018175188A1 (en) | 2017-03-21 | 2018-09-27 | Temple University-Of The Commonwealth System Of Higher Education | Novel modulators of the sigma-2 receptor and their method of use |
| TW202523659A (zh) | 2018-05-11 | 2025-06-16 | 美國坦普大學 高等教育聯邦系統 | 作為5-羥基色胺受體7之調節劑之新穎官能化內醯胺及其使用方法 |
| BR112022009361A2 (pt) | 2019-11-13 | 2022-08-09 | Univ Temple | Novas lactonas funcionalizadas como moduladores do receptor 7 de 5- hidroxitriptamina e seu método de uso |
| CN115003675A (zh) | 2019-11-13 | 2022-09-02 | 英联邦高等教育系统坦普尔大学 | 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法 |
-
2018
- 2018-03-15 WO PCT/US2018/022574 patent/WO2018175188A1/en not_active Ceased
- 2018-03-15 US US16/496,073 patent/US10961249B2/en active Active
- 2018-03-15 MA MA049019A patent/MA49019A/fr unknown
- 2018-03-15 JP JP2019551998A patent/JP7365237B2/ja active Active
- 2018-03-15 EP EP18772377.0A patent/EP3600290B1/en active Active
-
2021
- 2021-01-21 US US17/154,761 patent/US11820774B2/en active Active
-
2023
- 2023-10-06 JP JP2023174368A patent/JP7781122B2/ja active Active
- 2023-10-11 US US18/484,858 patent/US20240300954A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511506A5 (enExample) | ||
| JP2020511515A5 (enExample) | ||
| JP6982376B2 (ja) | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 | |
| KR101958501B1 (ko) | 설폭시민기 함유 4-아릴-ｎ-페닐-1,3,5-트리아진-2-아민 | |
| JP6026427B2 (ja) | 置換６，６−縮合窒素複素環化合物及びその使用 | |
| CN113365988A (zh) | Shp2抑制剂及其应用 | |
| JP6487925B2 (ja) | セリン／トレオニンキナーゼ阻害剤 | |
| TWI839363B (zh) | 嘧啶化合物及包括其之供預防或治療癌症的藥學組成物 | |
| DK2748151T3 (en) | Pyrimidine-pde10 inhibitors | |
| CA2749209C (en) | Indole derivatives as anticancer agents | |
| WO2014078813A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| UA71535C2 (en) | Corticotropine-releasing antagonists factor, methods for the preparation thereof, pharmaceuitical composition and a method for the treatment | |
| CN114129567A (zh) | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 | |
| CN103476759B (zh) | 取代的4-芳基-n-苯基-1,3,5-三嗪-2-胺 | |
| JP2007523152A5 (enExample) | ||
| TW201020244A (en) | New compounds | |
| EP2032538A2 (en) | Quinoline compounds and methods of use | |
| TW201217359A (en) | Novel compounds and compositions for the inhibition of NAMPT | |
| CN104918932B (zh) | 含磺亚胺基团的n‑(吡啶‑2‑基)嘧啶‑4‑胺衍生物 | |
| CN105283453B (zh) | 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物 | |
| JPWO2016006706A1 (ja) | テトラヒドロピラニルメチル基を有するピリドン誘導体 | |
| RU2017130825A (ru) | Гетероциклическое соединение и содержащая его фармацевтическая композиция | |
| JP2020503302A5 (enExample) | ||
| JP2019537592A5 (enExample) | ||
| JP2019537581A5 (enExample) |